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(57) ABSTRACT 
A particle composition comprising a graft copolymer formed 
from a biocompatible polymer and a plurality of polyamine 
moieties, wherein the polyamine moieties are bound to the 
biocompatible polymer, and a combinatorial delivery poly 
mer comprising a plurality of particles that comprises a graft 
copolymer of formed from a biocompatible polymer and a 
plurality of polyamine moieties, wherein the polyamine moi 
eties are bound to the biocompatible polymer, a plurality of 
nucleic acids electrostatically loaded onto the particles, a 
plurality of chemokine molecules, and a biodegradable poly 
mer network, in which the loaded particles and chemokine 
molecules may be entrapped, are disclosed. Also disclosed is 
a method for treating a Subject comprising administering a 
therapeutically effective dose of a pharmaceutical composi 
tion, the pharmaceutical composition comprising a particle 
composition that comprises a graft copolymer formed from a 
biocompatible polymer and a plurality of polyamine moi 
eties, wherein the polyamine moieties are bound to the bio 
compatible polymer. 
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FIGURE S. 
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FIGURE 6. 
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FIGURE 8. 
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FIGURE 9. 
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FIGURE 10. 
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FIGURE 11. 
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FIGURE 12. 
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FIGURE 15. 
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FIGURE 16, 
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1. 
POLYAMINE MODIFIED PARTICLES 
RELATED APPLICATION 
This application claims priority to U.S. provisional patent 
application No. 60/577,421, filed on Jun. 4, 2004, the full 
disclosures of which is incorporated herein by reference. 
BACKGROUND 
The present disclosure, according to one embodiment, 
relates to particle compositions modified with polyamines 
that may be used, among other things, in biomedical applica 
tions. 
Microparticle-based delivery of nucleic acids has gained 
particular attention in recent years in view of improving the 
potency of DNA vaccination. Such improvement has been 
reported by encapsulation of plasmid DNA (pDNA) within 
biodegradable microparticles or through Surface adsorption 
on cationic microparticles. However, the intrinsic intracellu 
lar barriers for gene delivery to antigen presenting cells 
(APCs) have not been adequately addressed in the rational 
design of delivery systems for DNA vaccines. 
Nucleic acid-based immunotherapy could provide new 
treatment options for a variety of complex disorders including 
infectious diseases, allergies and cancers. They are also less 
expensive, easy to mass produce and potentially safer alter 
native to currently available live or attenuated vaccines. 
pDNA vaccination using polymer microspheres have shown 
improved potency and excellent promise for human applica 
tions. Traditionally, such formulations have involved encap 
sulating pl)NA within the microspheres using emulsion 
based techniques. Recently, it was reported that plNA loaded 
on the Surface of cationic microparticles might provide sig 
nificantly improved immune response. Methods for synthe 
sizing such cationic microspheres have involved cationic Sur 
factants or physical blending of PEI or chitosan to PLGA 
particles. 
It has been shown that plNA encoding for particular anti 
gens can generate long-term humoral and cellular immunity 
with efficient generation of CD4"T helper cells and CD8" 
cytotoxic T cells in animal models. Specifically, DNA-based 
vaccines could have increased advantages over recombinant 
proteins and peptides in treatments of viral and parasitic 
infectious diseases as well as cancer whose resolution 
requires a strong CD8"T cell-mediated cellular immune 
response and a Th1-mediated humoral response. Since the 
first demonstrations of the efficacy of pDNA as vaccines most 
clinical trials have focused on naked plNA administration as 
the choice for delivery. Despite the widespread success of 
naked DNA in animal models, reproducible and robust clini 
cal efficacy in human trials is yet to be demonstrated. In recent 
years, significant research has focused on developing effec 
tive delivery systems and adjuvants for improving the 
potency of pDNA-based vaccination including polymer 
based particulate carriers, and novel immunomodulatory bio 
molecules (e.g. cytokines, CpG oligonucleotides, siRNA). 
Biodegradable polymer microparticle-based delivery sys 
tems have shown an enhancement of efficacy for genetic 
vaccines. These particles are believed to possess intrinsic 
adjuvant activity by passively targeting dendritic cells due to 
their size (0.5-10 um) and “foreign composition. Two major 
microparticle-based delivery strategies have been pursued: 
either encapsulating the plNA inside degradable micropar 
ticles or loading the anionic DNA on the surface of cationic 
particles. Although poNA encapsulated within poly(lactide 













exist some fundamental limitations to the approach including 
(a) low bioavailability of the DNA due to slow diffusional 
release, (b) low pH microenvironment created inside the par 
ticles during polymer degradation possibly compromising the 
bioactivity of plNA, (c) limited encapsulation efficiency, and 
(d) confinement of the microparticles inside phagolysosomal 
compartments leading to inefficient transfection. 
Surface loading of pDNA on cationic PLGA micropar 
ticles has shown significantly enhanced efficacy in animal 
models compared to naked DNA vaccines. This approach 
might have the advantage of (a) increased bioavailability, (b) 
improved loading efficiency, and (c) possible direct interac 
tion of the bacterial CpG sequences in the plasmid with endo 
somal toll-like receptor 9 (TLR9) leading to better dendritic 
cell activation. However, current approaches to synthesize 
cationic microparticles have involved cationic Surfactants or 
simple Surface adsorption or blending of branched polyethye 
leneimine (PEI) with PLGA, which rely on adsorption and 
physical entrapment of the cationic agent. This would likely 
suffer from pre-mature release of the molecules during for 
mulation or prior to reaching the target cells leading to Vari 
able efficacy as well as undesirable cytotoxicity. Therefore, 
improved methods to present pIDNA vaccines on particle 
Surfaces along with design strategies for better dendritic cell 
transfection could improve the efficacy of DNA-based immu 
nization. 
Another significant advantage of particle-based delivery is 
that they can be potentially used for combinatorial DNA and 
protein/peptide immunization in a single dosage formulation. 
This ensures the ability to strategically modulate the immune 
responses against a given antigen and generate a balanced 
humoral and cellular immunity. Studies of adjuvant effects of 
polymer particles encapsulating a protein/peptide antigen 
have demonstrated that these particulate carriers are readily 
internalized by dendritic cell in culture, leading to expression 
of markers for dendritic cell maturation. In addition, by an as 
yet unknown mechanism, particulate delivery, at least for 
peptide immunization, increases the antigen presentation 
efficacy significantly. 
Safe, yet effective adjuvants for vaccine applications are 
needed. Currently, aluminum salts (Alum) are the only FDA 
approved vaccine adjuvants in the US. However, its safety, 
efficacy and applicability in Stimulating a balanced humoral 
and cellular immunity in a wide range of vaccines, especially 
genetic vaccines, are questionable. 
SUMMARY 
According to a specific embodiment of the present disclo 
Sure, particle compositions comprising a graft copolymer of a 
biocompatible polymer bound to plurality of polyamine moi 
eties are provided. These particle compositions may further 
comprise one or more agents or one or more polymer net 
works, or both. 
In general, the compositions of the present disclosure may 
display beneficial pharmaceutical properties and provides an 
opportunity for improvements in the delivery of drugs, vac 
cines, diagnostic agents, and nucleic acids. The compositions 
of the present disclosure may be used in a variety of applica 
tions, including, but not limited to combinatorial delivery 
(e.g., the co-delivery of nucleic acids and agents. Such as 
therapeutic and diagnostic agents or imaging agents), thera 
pies for cancer, prophylactic therapies (e.g., vaccinations) 
against diseases (e.g., parasite, bacterial, and viral mediated 
diseases), imaging, drug delivery, and tissue engineering. 
According to a specific embodiment of the present disclo 
Sure, a chitosan graft copolymer particle composition com 
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prising a chitosan moiety, or a derivative thereof, and a 
polyamine moiety, or a derivative thereof, grafted together by 
the use of an activated chitosan or polyamine species or both 
are provided. 
According to a specific embodiment of the present disclo 
sure, PEI surface functionalized PLGA microparticles (PEI 
PLGA) are provided. Such compositions may be used as a 
delivery system with one or more of the following properties: 
(a) efficiently targets phagocytic cells (e.g. antigen presenting 
cells (APCs)), (b) remains non-toxic, among other things, 
because the attached PEI is surface immobilized in minimal 
quantities, (c) have intrinsic endosomal buffering and escape 
properties, among other things, due to the presence of sec 
ondary and tertiary amines on the Surface, (d) allows efficient 
loading of nucleic acids, (e) allows codelivery of immuno 
modulatory molecules (e.g., cytokines, siRNA, oligonucle 
otides) encapsulated inside the particles, (f) increases plNA 
bioavailability, and (g) may enhance cell maturation by 
allowing efficient activation of TLR9. The PEI-PLGA of the 
present disclosure may allow for better cell transfection and 
improved antigen presentation. 
According to a specific embodiment of the present disclo 
Sure, combinatorial delivery polymers are provided that com 
prise a plurality of biocompatible particle compositions, 
according to a specific embodiment of the present disclosure, 
that comprises a graft copolymer of a biocompatible polymer 
bound to plurality of polyamine moieties; a plurality of 
nucleic acids electrostatically loaded onto the particles; a 
plurality of chemokine molecules; and a biodegradable poly 
mer network, in which the loaded particles and chemokine 
molecules may be entrapped. 
FIGURES 
A more complete understanding of this disclosure may be 
acquired by referring to the following description taken in 
combination with the accompanying figures. 
FIG. 1 is a schematic showing the thiolation of chitosan, 
according to a specific example embodiment of the present 
disclosure. 
FIG. 2 is a schematic showing PEI grafting, according to a 
specific example embodiment of the present disclosure 
FIG. 3 is a graph showing the thiolation of chitosan with 
increasing amounts of 2-Iminothiolane, according to a spe 
cific example embodiment of the present disclosure. 
FIG. 4 is a graph showing the reduction in thiolation after 
PEI grafting, according to a specific example embodiment of 
the present disclosure. 
FIG. 5 is an FT-IR spectra of chitosan, chitosan-Trauts, 
chitosan-g-PEI600, and chitosan-g-PEI 1200, according to a 
specific example embodiment of the present disclosure. 
FIG. 6 is a transmission electron photomicrograph of nano 
complexes of (A) chitosan-g-PEI600/CMC with (wit/wt) 
ratios of 3.5:1; (B) chitosan-g-PEI600/CMC with (wit/wt) 
ratios of 7:1; (C) chitosan-g-PEI 1200/CMC with the (wit/wt) 
ratios of 3.5:1; and (D) chitosan-g-PEI 1200/CMC with the 
wit/wt ratios of 7:1; Scale 1 cm is equivalent to 208 nm, 
according to a specific example embodiment of the present 
disclosure. 
FIG. 7 is a graph showing the buffering ability of chitosan 
g-PEI600, according to a specific example embodiment of the 
present disclosure. 
FIG. 8 is a is a graph showing the cytotoxicity for a chito 
san-g-PEI, according to a specific example embodiment of 
the present disclosure 
FIG.9 is a transmission electron photomicrograph of nano 













5:1 in 5 mM sodium sulfate; (B) chitosan-g-PEI600/pDNA 
complexes at wit/wt ratio 5:1 in 5 mM sodium sulfate: Scale 1 
cm is equivalent to 208 nm, according to a specific example 
embodiment of the present disclosure. 
FIG. 10(A) is a graph of the Zeta potential analysis of 
PEI-conjugated and adsorbed PLGA microparticles in com 
parison with unmodified particles, according to a specific 
example embodiment of the present disclosure. 
FIG. 10(B) are scanning electron photomicrographs of (i) 
unmodified PLGA microparticles, (ii) PEI 70 k-conjugated 
PLGA microparticles and (iii) PEI 25 k-conjugated PLGA 
microparticles, according to a specific example embodiment 
of the present disclosure. 
FIG. 11 is a graph of acid titration experiments with 0.1 N 
HCl to demonstrate the buffering ability of PEI-conjugated 
and unmodified PLGA microparticles, according to a specific 
example embodiment of the present disclosure. 
FIG. 12 are photomicrographs showing the uptake of dex 
tran-rhodamine-encapsulated unmodified PLGA (A, B) and 
PEI 70 k-conjugated PLGA particles (C, D) in RAW264.7 
murine macrophage cells; (A) and (C) show differential inter 
ference contrast images and (B) and (D) show fluorescence 
images, according to a specific example embodiment of the 
present disclosure. 
FIG. 13 is a graph showing cell viability in the presence of 
PEI-conjugated or unmodified PLGA microparticles (N=3 
per group) after 24 hours of incubation; free PEI polymer was 
used for comparison, according to a specific example 
embodiment of the present disclosure, 
FIG. 14(A) is a graph showing p)NA loading levels on 
PEI-conjugated and unmodified PLGA microspheres, 
according to a specific example embodiment of the present 
disclosure. 
FIG. 14(B) is a photomicrograph showing DAPI staining 
of pDNA adsorbed on PEI 70 k-conjugated microparticles 
and simultaneous staining of surface-loaded plNA (DAPI) 
and co-encapsulated FITC-BSA on PEI 70 k-conjugated par 
ticles, according to a specific example embodiment of the 
present disclosure. 
FIG. 15(A) is a photograph of a gel electrophoresis after 
transfection of RAW 264.7 murine macrophage cell lines 
with PEI 70k- and PEI 25 k-conjugated PLGA microparticles 
using plasmid encoding for beta-galactosidase showing 
mRNA levels of beta-galactosidase 24 hours after transfec 
tion using RT-PCR, beta-actin was used as a house-keeping 
gene control, according to a specific example embodiment of 
the present disclosure. 
FIG. 15 (B) is a graph showing luciferase protein expres 
sion on RAW264.7 murine macrophage cell lines following 
transfection with PEI-conjugated PLGA particles with sur 
face-loaded plNA or with plNA encapsulated in PLGA 
particles, according to a specific example embodiment of the 
present disclosure; luciferase levels were measured 48 hours 
post transfection and normalized against total protein content 
measured using a BCA protein assay. 
FIG.16 is a schematic diagram showing the formulation of 
a vaccine, according to a specific example embodiment of the 
present disclosure. 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Patent Office upon request and payment of the necessary fee. 
While the present disclosure is susceptible to various modi 
fications and alternative forms, specific example embodi 
ments have been shown in the figures and are herein described 
in more detail. It should be understood, however, that the 
description of specific example embodiments is not intended 
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to limit the invention to the particular forms disclosed, but on 
the contrary, this disclosure is to cover all modifications and 
equivalents as defined by the appended claims. 
DESCRIPTION 
The present disclosure provides, according to certain 
embodiments, particle compositions comprising a graft 
copolymer of a biocompatible polymer bound to a plurality of 
polyamine moieties. As used herein, 'grafting” means a 
deposition technique whereby organic polymers can be 
bonded to a variety of other materials, both organic and inor 
ganic, in the form of fibers, films, chips, particles, or other 
shapes. As used herein, 'graft copolymers.” or grammatical 
variations thereof, means a polymer having branches of vary 
ing length made up of different monomeric units on a com 
mon chain. Among other things, the polyamine moieties may 
enhance transfection of the particle. These particle composi 
tions may further comprise one or more agents or one or more 
polymer networks, or both. The particle compositions should 
be of a size Suitable for use in a Subject (e.g., a human patient). 
The particles may have a size Suitable for injection into a 
Subject, such as a size in the micro or nano Scale (e.g., micro 
particles or nanoparticles). They also may be biodegradable. 
The polyamine moieties grafted to the particle may be any 
Suitable polyamine moiety, or derivative thereof. In general, 
the polyamine moiety may be chosen so as to enhance trans 
fection of the particle. The polyamine moiety should be 
bound to the particle by a covalent bond. Examples of suitable 
polyamines include, but are not limited to, polyethyleneimine 
(PEI), polyhistidine, putrescine, spermidine, and spermine. 
Other agents may be associated with the particles. By 
associated, it is meant that the agent may be bound, attracted 
to, attached, trapped, or encapsulated by the particle. 
Examples of Suitable agents include, but are not limited to, 
therapeutic agents, diagnostic agents, imaging agents, 
nucleic acids, pIDNA, immunomodulatory molecules (e.g., 
cytokines, siRNA or CpG oligonucleotides), proteins, and 
peptides. 
The biocompatible polymer suitable of use in the present 
disclosure generally should be capable of covalently binding 
a polyamine moiety. Examples of Suitable particles include, 
but are not limited to, chitosan, a chitosan moiety, poly(lac 
tide-coglycolide) (PLGA), and derivatives thereof. 
The particle compositions may have a residual positive 
charge for certain applications, such as when the particle 
compositions is to interact with a drug or a biological mem 
brane, to modify the tight junction of a mucosal Surface, or to 
coat a negatively charged particle. The particle compositions 
may retain Sufficient positive charge to allow it to interact 
with negatively charged (anionic) materials, such as oligo 
nucleotides or nucleic acids (e.g., DNA), and provide for 
compaction of the anionic materials. Compaction, as used 
herein, should be understood to mean a reduction in particle 
size as measured by a technique such as atomic free micros 
copy or photon correlation spectroscopy. The particle com 
positions may have sufficient positive charge to allow it to 
interact with negatively charged colloidal carriers intended 
for drug delivery (e.g., emulsions, liposomes, microspheres, 
and microcapsules), as well as negatively charged drug par 
ticles having a size less than about 100 nm. The particle 
compositions may have a sufficient positive charge to interact 
with mucin or epithelial cells. 
In drug targeting and drug delivery, as well as in diagnostic 
imaging and in the administration of vaccine systems, deliv 
ery materials in the form of emulsions, liposomes, micropar 













Such particles often carry a net negative charge. For some 
applications, it may be useful to modify this negative charge 
through, for example, the process of Surface modification. 
Accordingly, in certain embodiments, the present disclosure 
provides the modification of such delivery materials with 
particulate compositions so that the delivery materials carry a 
positive charge to, among other things, provide for Steric 
stabilization and beneficial biological and physical proper 
ties. 
The particle compositions may be used to compact plNA, 
which may have application in the field of gene therapy, 
among other things, because it is often important to be able to 
compact a plasmid material comprising nucleic acids into a 
small particle for improved administration. The resultant 
compacted product should have enhanced solubility and ben 
eficial properties for the interaction with cells and for the 
Subsequent expression of the gene product. 
In some examples, the particle compositions may be fur 
ther modified by the attachment of targeting ligands, for 
example, to the hydroxyl and unmodified amino functions. 
Such modification may provide, among other things, site 
specific targeting. Examples of Suitable targeting ligands 
include, but are not limited to, Sugars (e.g., mannose, fucose, 
and galactose) and proteins (e.g., monoclonal antibodies and 
fragments thereof). The specific Sugar chosen may dependon, 
among other things, the nature of the tissue or cell that is 
identified as the target site. For example, a chitosan grafted 
copolymer particle composition (described below) com 
plexed with DNA could be targeted to the liver by the covalent 
attachment of a triantennary galactose moiety. 
A positive charge on the particle compositions may be 
evaluated by studying the interaction of the copolymer with a 
negatively charged polymer So that a polyelectrolyte complex 
is formed as described by Terayama in J. Polymer Science, 
8:243 (1952). Alternatively, the particle compositions can be 
absorbed onto a polymer particle Such as a polystyrene micro 
sphere of about 1 micron in size and the charge on the system 
evaluated by particle microelectrophoresis using an appara 
tus such as the Malvern Zeta Sizer. 
A sufficient positive charge for interacting with the above 
described anionic species typically refers to a charge, mea 
sured as the Zeta potential, of at least about 1 mV and pref 
erably in the range of from about 1 to about 200 mV at about 
pH 7.4 in 1 mM HEPES buffer (or in 1 mM KCI). 
The particle compositions or adducts may be prepared 
using techniques known in the art, and described herein, for 
bonding polyamine moieties to polymeric materials. 
According to one embodiment, the present disclosure pro 
vides a chitosan grafted copolymer particle composition 
comprising a chitosan moiety, or a derivative thereof, and a 
polyamine moiety, or a derivative thereof, grafted together by 
the use of an activated chitosan or polyamine species or both. 
Chitosan grafted copolymer particle compositions in which 
the polyamine is PEI may be referred to as chitosan-g-PEI. 
The chitosan portion of the copolymer may have a molecular 
weight in the range of from about 10 kDa to about 1,000 kDa. 
According to another embodiment, the present disclosure 
provides a chitosan grafted copolymer particle composition 
comprising a graft copolymer that comprises a chitosan moi 
ety and a polyamine moiety (e.g., a PEI moiety), and a thera 
peutic agent, in which the therapeutic agent is formed from a 
plurality of nucleic acids (e.g., oligonucleotides). The 
polyamine moiety may be covalently bonded to the chitosan 
moiety and the therapeutic agent may be electrostatically 
loaded onto the particle. 
Chitosan is a polymeric material comprising repeating 
monomeric units having the formula: 












in which p is an integer and represents the number of mono 
meric units in the chitosan chain (i.e., the degree of polymer 
ization). 
In addition to the monomeric units shown above, chitosan 
will generally contain a proportion of the monomeric units 
found in chitin. This proportion will depend on the degree of 
deacetylation. Typically, the degree of deacetylation is in the 
range of from about 99% to about 10%, and may be in the 
range of from about 90% to about 20%, and may be in the 
range of from about 85% to about 40%. 
The degree of conversion of the chitosan to the grafted 
copolymer form may be varied by controlling the chemical 
reaction used to form the bonds. In this regard, a range of 
chitosan grafted copolymer complexes for different pharma 
ceutical applications may be provided. For example, the 
polyamine (e.g., polyethyleneimine, PEI) or polyhistidine 
moiety may increase the solubility of the grafted copolymer, 
or the polyamine may increase the solubility of a grafted 
copolymer complexed with atherapeutic agent (e.g., a drug or 
a nucleic acid). 
The amino (NH) or hydroxy (OH) or both may be con 
verted within chitosan to the grafted copolymer form within 
the range of from about 1 to about 99%. In some examples, 
however, the conversion may be in the range of from about 10 
to about 90%, and in other examples, in the range of from 
about 10 to about 50%. In general, not more than about 90% 
of the amine groups in chitosan should be bonded to provide 
the chitosan grafted copolymer with a Sufficient positive 
charge. The person skilled in the art will be able to ascertain 
the degree of conversion necessary to meet the required phar 
maceutical application. 
Chitosan can be obtained in a range of molecular weights 
from oligomeric materials containing a few units of glu 
cosamine through to higher molecular weight materials of 
more than 200,000 Da. In pharmaceutical applications, the 
higher molecular weights from about 50,000 to about 500, 
000 Da are normally preferred. Chitosan also may be 
obtained in different degrees of deacetylation. Chitosan hav 
ing a deacetylation of between about 60 and about 90% may 
be preferred. Chitosan can be obtained from various sources, 
including shellfish, fungi, and other materials. A pharmaceu 
tical grade of chitosan is commercially available from, for 
example, Pronova Limited of Norway. 
The chitosans used for the preparation of the chitosan 
grafted copolymer can have a molecular weight in the range 
of from about 10 kDa to about 1,000 kDa, from about 10 kDa 
to about 500 kDa, for example, about 20 kDa to about 500 
kDa, or from about 30 kDa to about 300 kDa, for example, 
between about 100 kDa and about 300 kDa. 
The degree of polymerization of the chitosans used in the 
preparation of a chitosan grafted copolymer particle compo 
sition may be in the range of from about 50 to about 6,000, 
from about 100 to about 3,000, or from about 150 to about 
2,000. 
As mentioned above, chitosans that have been derived by 
modification of the hydroxyl function may be used. Such 













as O-benzoyl chitosan and O-Sulphated chitosans, as detailed 
in A. F. Roberts, Chitin Chemistry, Macmillan, 166 (1992). 
Thus, in the present disclosure, the chitosan moiety in a 
chitosan grafted copolymer particle composition may be chi 
tosan, or a derivative thereof. 
As mentioned above, the chitosan grafted copolymer par 
ticle compositions may be used to modify Surfaces that are 
negatively charged, or to interact with or form complexes 
with negatively charged molecules such as DNA, pl.)NA, or 
nucleic acids. By way of explanation, and not of limitation, 
the positively charged chitosan of a chitosan grafted copoly 
mer particle composition may strongly bind a negative Sur 
face, which may expose the polyamine group to the external 
environment. Such exposed polyamine groups may provide 
for steric stabilization. Such stabilization may, among other 
things, lead to an improved stability (e.g., for a colloidal 
dispersion) and have important biological implications in 
minimizing the uptake of proteins to the Surface of a particle 
(e.g., when the particle is injected into the bloodstream or 
administered to a body compartment). 
The chitosan grafted copolymer particle compositions may 
be prepared using techniques known in the art for bonding 
polyamine moieties to polymeric materials. For example, the 
PEI-chitosan copolymer may be prepared by a process com 
prising thiolation of chitosan using 2-iminothiolane. In a 
related aspect, thiolation of chitosan may be confirmed by 
using Ellman's assay. In another related aspect, polyamines 
may be separately made thiol reactive by using an NHS ester: 
maleimide heterobifunctional linkers. Such thiol reactive 
polyamines may be grafted on chitosan and evaluated quali 
tatively by, for example, FT-IR spectroscopy. In another 
example, Achitosan grafted copolymer particle composition 
may be synthesized using carboxymethylcellulose (CMC) as 
a counter-ion. In a related aspect, such particles may be char 
acterized by, but not limited to, Zeta potential measurement, 
size analysis, and transmission electron microscopy. 
When used in drug delivery applications, the chitosan 
grafted copolymer particle compositions may provide advan 
tageous properties, particularly in relation to the physio 
chemical properties of the chitosan material and the interac 
tion of chitosan with surfaces, particles, and DNA. The 
chitosan grafted copolymer particle compositions of the 
present disclosure also may improve the paracellular trans 
port of drugs as already described for chitosan itself. More 
over, the chitosan grafted copolymer particle compositions 
may be used to form controlled release materials in the form 
of microspheres, microparticles, and matrices for administra 
tion to the gastrointestinal tract, to the vaginal cavity, to the 
nose, and to the buccal cavity. 
The chitosan grafted copolymer particle compositions also 
may be used for the administration of drugs to the eye wherein 
the chitosan would bind preferably to the mucus. In this 
regard, the chitosan grafted copolymer particle compositions 
may be used for the treatment of for example, dry eye syn 
drome, in which the polyamine moiety provides a steric sta 
bilization and lubricating effect. These products could be 
delivered to the eye using eye-drop systems known in the art. 
The chitosan grafted copolymer particle compositions may 
complex with carbohydrates such as alginates, Xanthans, dex 
tran Sulphate, and gellan. Accordingly, the chitosan grafted 
copolymer particle compositions may be useful for drug 
delivery applications. The chitosan grafted copolymer par 
ticle compositions also may interact with heparin and other 
negatively charged macromolecular drugs to form com 
plexes. Nasal and vaginal products as liquids or powders 
based on the chitosan grafted copolymer particle composi 
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tions may be delivered by conventional devices Such as spray 
pumps, powder insufflators, or Syringes. 
According to another embodiment, the present disclosure 
provides particle compositions comprising PEI Surface func 
tionalized PLGA particles (PEI-PLGA). The PEI covalently 
bound to the PLGA particle surface, which allows, among 
other things, efficient Surface loading of nucleic acids, intro 
duces intrinsic buffering properties to the resultant particle, 
and enhances transfection of phagocytic cells without affect 
ing the cytocompatibility of PLGA carriers. Accordingly, 
PEI-PLGA particles may be capable of simultaneously deliv 
ering both DNA vaccines, as well as other immunomodula 
tory agents (e.g., cytokines or nucleic acids that are entrapped 
or encapsulated inside), within a single injectable delivery 
vehicle. Such compositions may be used in applications such 
as, for example, microparticle-based delivery of nucleic 
acids, proteins and peptides, and DNA vaccination. The com 
binatorial delivery polymers may be used to enhance the 
adjuvant effects of microparticles for genetic immunization 
and allow for safe yet highly efficacious vaccine formation. 
In general, PEI is covalently bound to PLGA to form PEI 
PLGA. Such covalent binding may be accomplished by 
covalently conjugating branched PEI or linear PEI using car 
bodiimide chemistry to the surface of PLGA. The resulting 
PEI-PLGA particle may be a cationic microparticle, which 
may then be complexed with an agent. The agent may be 
entrapped inside the PLGA matrix or presented on the surface 
or both. Examples of suitable agents include, but are not 
limited to, pIDNA, immunomodulatory molecules (e.g., 
cytokines, siRNA or CpG oligonucleotides), proteins, pep 
tides, and nucleic acids. For example, pIDNA may be pre 
sented on the surface of a PEI-PLGA, while an immuno 
modulatory molecule may be incorporated inside the PLGA 
matrix. Surface presentation of pDNA may, among other 
things, allow for increased bioavailability from more efficient 
release of the plNA (e.g., by competitive cationic (salt) inter 
actions in the cytoplasm). Immunomodulatory molecules 
may, among other things, further aid in the process of 
crosstalk during the priming of naive T cells. Such complexed 
PEI-PLGA may be used for therapeutic or diagnostic delivery 
of the agent. 
According to another embodiment, the present disclosure 
provides a combinatorial delivery polymer comprising a plu 
rality of particles that comprise a graft copolymer of a bio 
compatible polymer bound to plurality of polyamine moi 
eties, a plurality of nucleic acids electrostatically loaded onto 
the particles, a plurality of chemokine molecules, and a bio 
degradable polymer network in which the loaded particles 
and chemokine molecules may be entrapped. The combina 
torial delivery polymer may be used in a variety of applica 
tions such as, for example, combinatorial delivery (e.g., the 
co-delivery of nucleic acids and chemokines and optionally 
other agents). Other applications include, for example, thera 
pies for cancer, prophylactic therapies (e.g., vaccinations, 
Such as nucleic acid vaccines) against diseases (e.g., parasite, 
bacterial, and viral mediated diseases), imaging, drug deliv 
ery, and tissue engineering. The particle may be a biodegrad 
able, polymer particle surface modified to attach branched or 
linear polyamines, for example, a PEI-PLGA microparticle. 
The surface functionalization of PLGA microparticles using 
polyamines carrying secondary and tertiary amines (e.g., 
PEI) may enhance endosomal escape of the particles leading 
to increased transfection efficacy. Accordingly, covalent con 
jugation of branched and linear polyethyeleneimine on the 
particle Surface using modified carbodiimide chemistry may 
be used to form the particle. Covalent conjugation, as 













certain applications because, among other things, free PEI 
may be cytotoxic and PEI is a highly hydrophilic molecule, 
which may diffuse out of the particle surface when placed in 
Solution. Accordingly, certain examples of combinatorial 
delivery polymers, the amount of PEI is controlled to create a 
cationic particle surface and free PEI is minimized. Covalent 
conjugation also provides batch-to-batch reproducibility and 
a stable formulation by avoiding the inherent variability in the 
adsorption process. 
Such PEI-PLGA microparticles are cationic, and may 
allow electrostatic loading of nucleic acids. Examples of 
nucleic acids that may be loaded on the particle include, but 
are not limited to, plNA or CpG oligonucleotides, individu 
ally or in combination. Surface presentation of CpG oligo 
nucleotides (e.g., as part of the plasmid backbone or in addi 
tion to the plNA) on particulate carriers may allow for 
efficient activation of, for example, the toll-like receptor 9 
(TLR-9) in the phagocytic pathway. 
A plurality of chemokine molecules may be included in the 
combinatorial delivery polymer, or the chemokine molecules 
may be included in the particles (e.g., by encapsulation in the 
particles). As used herein, the term chemokine also refers to 
cytokines and chemo-attractants. Any chemokine molecule 
may be used. The specific chemokine chosen may depend on, 
among other things, the immunological requirements (e.g., 
the site of administration, antigen, target cells, and the like). 
Examples of suitable chemokine molecules include, but are 
not limited to, MIP-3?, MIP-3C. (e.g., for cutaneous and 
mucosal Langerhans cells), monocyte chemotactic proteins, 
for example, MCP-1 and MCP-3 (e.g., for intramuscular 
applications). 
The plurality of chemokine molecules and the plurality of 
loaded particles are entrapped within the biodegradable poly 
mer network. The biodegradability of the polymer network 
allows for efficient target cell migration and loaded particle 
uptake while releasing the chemokines at an optimum dose. 
Such a strategy creates a depot system for both chemokines 
and particles. This may, among other things, enhance the 
adjuvancy of the particle formulation, allow for more efficient 
delivery of the plNA antigen, and ultimately augment the 
immune response in a Subject. 
The polymer network may be any polymer network 
capable of being injected into a Subject and that is capable of 
gelling inside the tissue following injection. Any amount of 
chemokine may be entrapped within this network without 
loss of activity during the formulation process. The polymer 
network may be tuned to tailor the chemokine release profile 
for a desired application. One example of a Suitable polymer 
network is an in situ crosslinking, biodegradable, hydrogel 
network, as described in Roy, et al., MolTher 7:401-8 (2003). 
Such polymer networks are based on chemical crosslinking 
between nucleophilic and an electrophilic PEG molecules 
that forms a network following administration thereby trap 
ping any co-delivered biomolecule into a depot system. The 
network is also biodegradable due to the presence of a hydro 
lytically labile ester bond in the backbone of the PEG elec 
trophile. Encapsulated molecules are released over time via 
diffusion and by continuing degradation of the network. Such 
a network is simple and injectable, made up of FDA 
approved, biocompatible polymers that can be easily scaled 
up and manufactured for clinical usage. 
Combinatorial delivery polymers may be used to treat a 
Subject (e.g., a human patient). By way of explanation, and 
not of limitation, a specific example embodiment of a com 
binatorial delivery polymer may operate as a vaccine as 
shown in FIG. 16. In this combinatorial delivery polymer 
sustained release of the chemokines from the hydrogel would 
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attract naive (immature) dendritic cells to the site of admin 
istration and directly to the nucleic acid carrying micropar 
ticles. The particles, due to their inherent synthetic (foreign 
biomaterial) property and size (microns, resembling the size 
of pathogens), would be readily phagocytosed by the den 
dritic cell. Within the endosomal pathway, the surface 
adsorbed plNA and CpG could interact with TLR-9 and 
initiate an NF-kB mediated response leading to activation and 
maturation of the dendritic cell. The availability of secondary 
and tertiary amines on the particle Surface would enhance the 
buffering capacity of the particles and due to the proton 
sponge mechanism, could allow for more efficientendosomal 
escape. This would enhance plNA delivery to the cytoplasm 
and increase transfection. Maturation of the dendritic cell 
would lead to migration to the secondary lymphoid organs 
where the expressed antigen will be presented to the T cells. 
Accordingly, some combinatorial delivery polymers of the 
present disclosure may be used, among other things, as a 
strong yet safe adjuvant leading to a stronger immune 
response against the pDNA encoded antigen. 
Sustained release of chemokines from the polymer max 
enhance migration of immature Langerhans cells to the 
injection site and lead to more efficient particle uptake and 
improved antigen presentation. Although bolus injection of 
MIP-3C. along with the pDNA carrying microparticles might 
be effective, proteins and peptides are rapidly cleared away 
due to fast diffusion and degradation in tissues. The combi 
natorial delivery polymer, however, provides a Sustained gra 
dient of chemokines (e.g., MIP-3C.), which may increase both 
the number of immature dendritic cells at the site of admin 
istration and the duration of their presence. An alternative 
design would be encapsulation of a chemokines inside the 
Surface functionalized particles during their formation (e.g., 
during formation of the particles using a double emulsion 
process). 
To facilitate a better understanding of the present inven 
tion, the following examples of specific embodiments are 
given. In no way should the following examples be read to 
limit or define the entire scope of the invention. 
EXAMPLES 
Example 1 
An example of a chitosan-g-PEI and chitosan-g-PEI com 
plex, according to a specific example embodiment of the 
present disclosure, was formed and studied as follows. 
Materials and Methods. 
Preparation of PEI-chitosan Using Activated PEI: Chito 
san Average MW -250,000 Da, Vanson Polymers, WA) was 
thiolated using 2-Iminothiolane as shown in FIG. 1 and as 
described Cui, et al. Journal of Controlled Release 75:409-19 
(2001), Constantia, et al. International Journal of Pharmaceu 
tics 256:183-89 (2003), and Bemkop-Schnurch, et al., Euro 
pean Journal of Pharmaceutics and Biopharmaceutics, 57:9- 
17 (2004). Briefly, a 5% chitosan solution was adjusted to pH 
6.5, to which 2-Iminothiolane was added in quantities of 0.5x, 
1x, 2x, or 5x (SH:NH2). The reaction was allowed to proceed 
at room temperature under magnetic stirring for 24 hours. The 
resulting solution was dialyzed using 10 KDaMW Cutoff for 
2 days using 1% NaCl and 5 mM HCl to keep the pH low and 
prevent oxidation of sulfhydryls. 
The resulting conjugates were lyophilized and stored under 
desiccation. Thiolation of chitosan was confirmed with an 
Ellman's assay using Ellman’s reagent (5.5'-Dithio-bis-(2- 
nitrobenzoic acid), DTNB). Briefly, 50 ul of stock DTNB 













8.0 and added to 0.5 mg of hydrated chitosan and thiolated 
chitosan samples. The samples were centrifuged after reac 
tion at room temperature for 2 hours, and the Supernatant was 
read 450 nm and compared with standard curves established 
with thioglycolic acid with r=0.9989. 
PEI (MW 600 and 1200 Da. Polysciences Inc., PA) was 
separately made thiol reactive by using water-soluble analogs 
of NHS ester: maleimide heterobifunctional linkers reacted 
together at room temperature for about 1 hour. Control 
batches had thiolated chitosan with PEI600 without 
crosslinker during the process of grafting. This thiol reactive 
PEI (crosslinker activated PEI600) was then reacted over 
night with the sulfhydryl modified chitosan to form the graft 
(chitosan-g-PEI). FIG. 2 shows a schematic of PEI grafting. 
All batches were dialyzed alike to remove nongrafted, excess 
PEI molecules using Snake Skin Dialyzer (MW cutoff 3.5 
KDa, Pierce Biotechnology Inc., IL) for 2 days using 1% 
NaCl and 5 mM HCl to keep the pH low and prevent oxidation 
of sulfhydryls. The resulting conjugates were lyophilized and 
stored under desiccation until further analysis. 
Thiolation of chitosan was confirmed with an Ellman's 
assay. Briefly, 5 mg of control chitosan, thiolated chitosan, 
and PEI grafted chitosan were hydrated in 250 ul of deionized 
water, and 50 ul of stock DTNB solution was diluted in 700 ul 
of 0.5M phosphate buffer pH 8.0 and added to the hydrated 
samples. The samples were centrifuged after reaction at room 
temperature for 2 hours, and the supernatant was read at 450 
nm and compared with standard curves established with 
thioglycolic acid with r=0.9974. 
Lyophilized grafts were used for FT-IR studies. FT-IR 
experiments were done using KBr pellets made by homog 
enously mixing 2 mg of chitosan, sulfhydryl modified chito 
san and the PEI grafted chitosan with 300 mg of KBr. FT-IR 
spectra were recorded using plain KBrpellets forbackground 
Subtraction using 32 interferograms with 4 cm resolution on a 
Nicolet Magna IR-560 FT-IR Spectrophotometer. 
Complexes were synthesized using a simple technique as 
described in Mize Benis, et al., Gene Therapy 7:2105-12 
(2000) using a chitosan (or chitosan-g-PEI)/CMC (wt/wt) 
ratios of 3.5:1. Transmission Electron Micrographs were 
taken on a Philips 208 TEM. The particle sizing and Zeta 
Potential Analysis were performed using a Zeta Plus Ana 
lyzer (BrookHaven Instruments, Holtsville, N.Y.). 
Buffering ability of chitosan-g-PEI: The ability of chito 
san-g-PEI to resistacidification was tested using acid titration 
assay as described in Tang, et al., Gene Ther 4(8):823-32 
(1997). Briefly, 10 mg/mL of lypholyzed chitosan-g-PEI was 
suspended in 150 mM NaCl. The pH was first adjusted to 9.0 
and then titrated in small increments with 0.1 NHCl until a 
pH of 3.5 was reached. The slope of the pH versus HCL added 
graph provides an indication of the intrinsic buffering capa 
bility of the chitosan-g-PEI. 
Cytotoxicity evaluation for chitosan-g-PEI: Preliminary 
toxicity evaluations of chitosan-g-PEI were conducted in 
comparison with commercially available transfection agents 
and unmodified chitosan. Cytotoxicity evaluation was con 
ducted by incubating cells with free polymers in 1x, 5x, and 
10x concentrations higher than that needed for transfection 
(N:Pratio of 6:1 was chosen). An MTT (3-4,5-dimethylthi 
azol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used 
to evaluate the cytotoxicity of cationic microparticles. 
Twenty thousand RAW murine macrophage cells were 
seeded on tissue-culture-treated 96-well plates and cultured 
overnight. Cells were incubated with the formulations for 24 
hours, rinsed with PBS, and cytotoxicity was evaluated using 
MTT according to the manufacturer's protocol with untreated 
cells as negative control. Cell viability was conducted by 
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comparing the amount of MTT utilized by live cell mitochon 
drial dehyrogenases to produce formazan crystals which are 
solubilized using acidified isopropanol and absorbance read 
ings were taken on a microplate spectrophotometer at 570 
. 
Results. 
Thiolation of Chitosan: 2-Iminothiolane successfully con 
verted -24% of the primary amine groups in the backbone of 
chitosan to carry a free sulfhydryl group (FIG.3 and FIG. 4). 
Thiol quantification by Ellman’s assay was done with stan 
dard curves established using thioglycolic acid. Statistical 
analysis on the reproducibility of thiolation was done using 
ANOVA. Statistical significance between the controls and the 
samples were established using a one tailed t-test (P<0.01). 
FTIR Spectra of PEI grafting on Thiolated Chitosan: PEI 
grafting can be indicated from the FT-IR spectra of unmodi 
fied chitosanandchitosan-g-PEI (FIG. 6), which indicates the 
appearance of a doublet peak at 1600. Such peaks are indica 
tive of the presence of secondary amines in the grafted poly 
mer. Since chitosan does not carry any secondary amine 
groups, it is a signature of the presence of PEI. Furthermore, 
the increase in carbonyl Stretching indicates the presence of a 
thioester linkage formed between SH and maleimide. Also 
seen is the relative increase in the height of the carbonyl 
stretching and NH bending peaks in the PEI grafted polymer 
compared to the height of the C Opeak seen at 1075 in the 
control samples. Relative changes in the heights of the peaks 
at CH stretching at 2900 in comparison with the OH stretch 
ing which is consistent in the PEI grafted chitosans and 
significantly smaller in the control chitosan samples. 
Nanocomplexes formed by Complex Coacervation with 
CMC: FIG. 7 shows that nanocomplexes formed with Chito 
san-g-PEI are similar in appearance with unmodified Chito 
San complexes. 
Sizing and Zeta Potential: chitosan-g-PEI nanocomplexes 
showed an increase in the mean size of particles with increas 
ing molecular weight of the grafted PEI. In addition, the Zeta 
potential of particles formulated with these graft copolymers 
are significantly higher indicating the presence of highly 
charged branched PEI on the surface as shown in Table 1. 
TABLE 1. 
Type of Complex (wt wt) Size (nm) Zeta Potential in mV. 








59.91 +f- 0.438406 
328.3 +f-115.117 76.285 +/- 0.502046 
Buffering ability of chitosan-g-PEI: Weight analysis of the 
lyophilized grafts indicated a three fold increase for the 
grafted polymers compared to the controls postgrafting. Con 
sidering that equal weights of the chitosan and chitosan-g- 
PEI were used in titration it could be estimated that the graft 
carrying an equivalent weight of chitosan in addition to the 
grafted PEI would have thrice the buffering ability (FIG. 8). 
Cytotoxicity evaluation for chitosan-g-PEI: As shown in 
FIG. 8, chitosan-g-PEI was found to be considerably toxic at 
5x and 10x concentrations in comparison with unmodified 
chitosan, while chitosan and PEI600 incubated with cells did 
not prove toxic suggesting possible toxicity issues of either 
thiolated chitosan or the crosslinker. 
Example 2 
In order to demonstrate the difference between the com 













with an example of a chitosan-g-PEI, according to one 
embodiment of the present disclosure, a model plasmid mate 
rial can be employed. This may be in the form of a plasmid 
such as CMV-CAT (pCAT) that encodes for chloramphenicol 
acetyl transferase (CAT), a so-called reporter gene system, 
commercially available from Gene Medicine, Inc., Houston, 
USA, or pgWiz Luciferase, commercially available from 
Aldevron LLC., ND. 
Complexes were synthesized using a simple technique as 
described in Mize Benis, et al., Gene Therapy 7:2105-12 
(2000) using a chitosan (or chitosan-g-PEI)/CMC (wt/wt) 
ratios of 3.5:1. The pCAT-DNA/chitosan or the pCAT-DNA/ 
chitosan-g-PEI complexes is prepared to give different pCAT 
DNA/polymer ratios. The size of chitosan and PEI-chitosan 
complexes and their Zeta potentials in water and 1 mM 
HEPES buffer at pH 7.4 is determined using a MalvernS4700 
PCS and a Malvern Zeta Sizer (Mark IV) (or a ZetaPlus 
machine (BrookHaven Instruments Corp., NY)), respec 
tively. Transmission Electron Micrographs were taken on a 
Philips 208 TEM. 
FIG. 9 shows that nanocomplexes formed with chitosan 
g-PEI are similar in appearance with unmodified chitosan 
complexes (compare to FIG. 6). The size and Zeta potentials 
are shown in Table 2 (compare to Table 1). 
TABLE 2 
Type of Complex (wt?wt) Size (nm) Zeta Potential in mV 
Chitosan-g-PEI600/pLNA 262 20.35 31.67 + 1.28 
Chitosan?pDNA 2923 - 52 NA 
It will be appreciated by those skilled in the art that the size of 
the resulting complexes between plasmid DNA and a com 
pacting polymer will be affected by the ratio of the interacting 
components and the processing conditions. 
Example 3 
An example PEI-PLGA and PEI-PLGA complex, accord 
ing to one embodiment of the present disclosure, was formed 
and studied as follows. 
Materials and methods. 
Polymers and Reagents: PLGA RG502H (Boehringer 
Ingelheim, VA (I.V=0.16-0.2 dL/g, MW ~11,000 Da), Poly 
(vinyl alcohol) MW -31,000 (88% hydrolyzed) was pur 
chased from Fluka. Branched PEI, MW=-70,000 Da was 
from Poly-sciences Inc., PA, and MW=-25,000 Da was from 
Sigma Aldrich, MO. Rhodamine conjugated Dextran (MW 
-70,000 Da), Streptavidin-FITC, and DAPI Nuclear Stain 
were obtained from Molecular Probes, OR. Plasmids pgWiz 
Luciferase and pgWiz, B-galactosidase were from AldeVron 
LLC., ND. Anti-LAMP-1 antibody and Goat Anti Rat IgG2a 
biotin was purchased from Pharmingen (BD BioSciences), 
CA. 
Cell lines and cell culture products: RAW264.7 murine 
macrophage cell line was obtained from AmericanType Cul 
ture Collection (ATCC, VA). ATTC-modified DMEM were 
used to maintain these cells. All other reagents for cell culture 
were purchased from Invitrogen, CA. 
Synthesis of water-in-oil-in-water (w/o/w) emulsion 
microparticles: PLGA microparticles were synthesized using 
a w/ofw double emulsion, Solvent evaporation technique. 
Briefly, 0.35 g of acid end-terminated PLGA was dissolved in 
7 mL of methylene chloride (EMD Chemicals, NJ).300 uL of 
deionized water was added to this polymer Solution and 
homogenized at 10,000 rpm for 2 minutes using a Silverson 
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SL2 T homogenizer (USA). This primary emulsion was 
poured into 50 mL of 1% PVA solution and homogenized for 
1 minute to obtain a w/o/w emulsion followed by solvent 
evaporation for 3 hours. Microparticles formed were washed 
3 times with deionized water, lyophilized and stored at -20° 
C. The particles were further characterized with respect to 
size, Zeta potential (ZetaPlus, BrookHaven Instruments, NY) 
and by scanning electron microscopy (SEM, Philips 515). 
Fluorescent microparticles were synthesized using dextran 
rhodamine in the internal aqueous phase (1 mg/mL in water) 
and remaining steps were unaltered. FITC conjugated BSA 
(Sigma Aldrich, St Louis, Mo.) was also incorporated in the 
primary emulsion during the process of particle synthesis 
followed by surface modification with PEI as described 
below. pl.)NA encapsulated in PLGA microparticles were 
synthesized as previously described by McKeever, et al. Vac 
cine 20(11-12): 1524-31 (2002) and Roy, et al. In: Fifth Cold 
Spring Harbor conference on genetherapy, Sep. 25-29, 2000, 
New York: Cold Spring Harbor Laboratory. 
Synthesis of cationic microparticles: A modified EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro 
chloride)/NHS chemistry was used to conjugate PEI to the 
surface of PLGA microspheres to obtain cationic micropar 
ticles. Briefly, 20 mg of PLGA microparticles was suspended 
in 800 mL of 0.1 MMES (2-(N-morpholino)ethane sulfonic 
acid) buffer, pH 5.1. EDC (Pierce Biotechnology Inc., IL) and 
water soluble sulfo N-hydroxysuccinimide (Sulfo NHS) 
(Pierce Biotechnology Inc.) in 40 molar excess were dis 
solved in ice cold 0.1 M 2-Morpholinoethane-sulfonic acid 
(MES) buffer and added dropwise to the PLGA particle sus 
pension. EDC activation was done for 2 hours at room tem 
perature. Five molar excess of 70 kDa branched PEI (Poly 
sciences Inc., PA) or 15 molar excess of 25kDa branched PEI 
(Aldrich, Wis.) was diluted in 9 mL of 0.1 M MES buffer. 
Activated PLGA microparticles were added dropwise to the 
PEI solution with magnetic stirring and incubated for another 
2 hours at room temperature. PEI-conjugated microparticles 
were washed 4x in excess 1 M NaCl to remove physically 
adsorbed PEI and the resulting microparticles were lyo 
philized and stored at 20° C. Fluorescent cationic micropar 
ticles were synthesized by conjugating PEI (70 or 25 kDa) to 
the surface of dextran-rhodamine-entrapped PLGA micro 
particles. FITC-BSA entrapped PLGA-PEI particles were 
synthesized similarly and used for plNA loading and confo 
cal studies. PEI-adsorbed particles were synthesized as 
described above except for EDC-NHS activation. 
Fluorescamine assay for quantification of PEI: Fluores 
camine (4-phenylspirofuran-2(3H), 1'-phthalan-3,3'-dione) 
has been used for colorimetric quantification of primary 
amines and to quantify PEI associated with microparticles. 
PEI-conjugated microparticles were hydrolyzed in 0.1 N 
NaOH overnight and the PEI content was measured using 
spectro-fluorometric analysis. Fluorescamine reacts with pri 
mary amines in PEI to form pyrrolinones, which is excited at 
390 nm and has emission peak at 475-490 nm. PEI amounts 
(w/w) in microparticles were estimated using standard curves 
of PEI. All measurements were performed on a Fluoroplate 
Reader (BioTek, Vermont). 
Buffering ability of PEI-conjugated PLGA microparticles: 
Ability of PEI-conjugated PLGA microparticles to resist 
acidification was tested using acid titration assay as described 
above. 
Cytotoxicity evaluation using MTT assay: MTT assay was 
used to evaluate the cytotoxicity of cationic microparticles as 
described above. Briefly, twenty thousand RAW murine mac 
rophage cells were seeded on tissue-culture-treated 96-well 














were added at doses of 0.25,0.5, and 1.0 mg/mL in 0.2 mL of 
complete cell culture medium. The concentrations of poly 
meric particles were chosen from an estimated plNA loading 
of 10 ug/mg and an equivalent pINA dose of 500, 1000 and 
2000 ng/well. The PEI polymer amounts used were for 
equivalent amount of pDNA dose using a 9:1 N:Pratio. Cells 
were incubated with the formulations for 24 hours, rinsed 
with PBS, and cytotoxicity was evaluated using MTT accord 
ing to the manufacturer's protocol with untreated cells as 
negative control. 
Confocal microscopy: In order to confirm the increased 
buffering ability noticed using acid titration experiments, 
confocal microscopy was used to study cell uptake and 
phago-Somal trafficking. RAW murine macrophage cell line 
was used as a model phagocytic system. 0.5x10° cells were 
seeded overnight on fibronectin (Sigma Aldrich, MO)-coated 
glass coverslips. Dextran-rhodamine-entrapped unmodified 
PLGA or PEI-modified PLGA microparticles were added to 
the wells at 50 mg/mL and incubated for 4-6 hours at 37° C. 
Cells were fixed with 4% paraformaldehyde for 30 minutes 
and permeated using 0.2% Triton X-100 (Avocado Chemi 
cals, MA). Fixed and permeated cells were blocked with 1% 
BSA and a rat antimouse CD107a (LAMP-1) (Pharmingen, 
BD Biosciences, CA) antibody was used to stain lysosomes 
followed by biotinylated Goat anti Rat IgG2a and Streptavi 
din-FITC. Nuclei were counterstained with DAPI and con 
trols were performed to evaluate background staining with 
the secondary antibody and the Streptavidin-FITC but with 
out any primary anti LAMP-1 antibodies. Cells were imaged 
using a LEICA Confocal Laser Scanning Microscope with a 
63x oil immersion objective. 
Plasmid DNA loading on cationic microparticles: pgWiz 
Luciferase was loaded on the Surface of cationic micropar 
ticles as described in Singh, et al. Proc Natl Acad Sci USA 
97(2):811-6 (2000). Briefly, plDNA loading was attempted at 
1% w/w by incubating plNA with the cationic microparticle 
suspension in PBS, pH adjusted to 6.5, at 4°C. for 6 hours. 
pDNA was also adsorbed on control (unmodified) PLGA 
microparticles using the same conditions as for the cationic 
particles. The resulting particles were centrifuged at 12,000 
rpm for 15 minutes on a microcentrifuge and washed 2x with 
the loading buffer. The Supernatant was collected and ana 
lyzed spectrophotometrically (A260 nm) for plNA content. 
pDNA loading on the cationic microparticles was calculated 
by subtracting the plNA content in the supernatant from the 
initial concentration of pDNA added. In addition, pl.)NA 
loading was also analyzed directly by hydrolyzing the DNA 
adsorbed particles overnight in 0.1 N NaOH and evaluating 
the DNA concentration spectrophotometrically. The total 
pDNA calculated both by direct and indirect methods were in 
COCUCC. 
Evaluation of transgene mRNA levels in RAW murine 
macrophage cell lines using RT-PCR: For RT-PCR evalua 
tion, RAW cells were seeded at 0.5x106 cells/mL in six-well 
plates. Untreated cells were chosen as negative controls. 
Comparative studies were performed using 3 ug of pgWiz 
B-galactosidase adsorbed on 70 or 25kDa PEI-modified cat 
ionic PLGA microparticles. Following 24 hours incubation in 
complete serum medium, cells were rinsed and lysed using 
Trizol R (Invitrogen, CA) and stored at 80°C. before isolation 
of total RNA. Total RNA was isolated using chloroform phase 
separation/ethanol precipitation and reconstituted in DEPC 
treated water (Invitrogen, CA). RT-PCR (AccessOuickTMRT 
PCR System, Pro-mega, WI) of the total RNA was performed 
using a B-gal specific 500 bp amplicon (Applied BioSystems, 
CA). Housekeeping gene B-actin was chosen as a positive 
control using a 573 bp primer (Invitrogen, CA). RT enzyme 
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free samples were used as DNA contamination control. All 
PCR reactions were performed using standard PCR condi 
tions. 
Evaluation of luciferase expression in RAW cells: 5x104 
cells were seeded in 96-well tissue culture treated plates 
(Costar, Fischer Scientific). Microparticle formulations with 
pgWiz, Luciferase DNA adsorbed were added at plNA 
equivalent doses of 100, 300 and 900 ng/well in triplicates. 
For comparisons with encapsulated formulations, pINA was 
encapsulated as previously described. Cells were incubated 
with these formulations, in complete serum medium, for 48 
hours at 37°C., washed with sterile PBS, lysed using the Glo 
Lysis Buffer (Promega, WI) and lysates divided equally for 
luciferase content and total protein content analysis. 
Luciferase was assayed (Dynex Plate Reading Luminometer) 
using the Bright Glo Luciferase Assay System (Promega, WI) 
according to manufacturer's protocol. Total protein content 
was determined using a Micro BCA protein assay kit (Pierce 
Biotechnology, IL). The luciferase content obtained from the 
luminescence readings was normalized to the total protein 
COntent. 
Statistical analysis: Single Factor ANOVA was used for 
unequal variances to establish significant between the 
adsorbed and the conjugated batches and a PK0.05 was con 
sidered to be significant. 
Results 
Covalent conjugation is a reproducible method for fabri 
cating highly cationic, biodegradable microparticles: PEI 
was successfully conjugated on the Surface of PLGA micro 
particles using a simple, EDC-NHS chemistry. Surface modi 
fication was characterized by Zeta potential analysis while 
conjugation of PEI was quantified using a fluorescamine 
assay. As shown in FIG. 10A, PEI-modified particles show 
significantly positive Zeta potential indicating a positively 
charged surface. Unmodified particles exhibit a negative Zeta 
potential arising from the Surface carboxyl groups. It is evi 
dent that covalent conjugation yields a significantly higher 
Zeta potential (+35 mV) compared to simple Surface adsorp 
tion of PEI (+10 to 24 mV). In addition, our results from 
multiple experiments (data not shown) suggest that the 
adsorption process is highly variable and poorly reproduc 
ible. On the other hand, the conjugation process produces a 
fairly reproducible charged Surface. Fluorescamine quantifi 
cation of PEI indicated that the amounts of PEI present on 
particle surface are 6.5ug for PEI 70 kDa and 5-6 ug for PEI 
25 kDa per microgram of microparticles. SEM analysis of 
PEI-conjugated and unconjugated particles indicate no sig 
nificant change in surface morphology (FIG. 10B). These 
results indicate that covalent conjugation of PEI on the sur 
face of biodegradable PLGA microparticles produces highly 
reproducible cationic particles with minimal amount of PEI 
present on the particle Surface. 
PEI conjugation imparts buffering properties to PLGA 
microparticles: We hypothesized that covalent surface modi 
fication of PLGA particles with branched polyamines carry 
ing secondary and tertiary amines might enhance endolyso 
somal pH buffering which could lead to increased 
phagosomal escape of the carrier particles (proton Sponge 
mechanism). The buffering capacity of PEI-conjugated par 
ticles was assessed by measuring the change in pH of a 
particle Suspension (10 mg/mL) upon addition of increasing 
amounts of 0.1 N HC1. As shown in FIG. 11, significant 
buffering ability is imparted on PLGA particles upon conju 
gation of PEI, especially with the 70 kDa molecular weight 
PEI. This is indicated by the shift and a decrease in the slope 













Surface functionalization of PLGA microparticles allows 
early phagosomal escape: The intracellular distribution of 
unmodified and PEI-conjugated, dextran-rhodamine-en 
trapped PLGA microparticles were evaluated by confocal 
fluorescence microscopy. FIG. 12 shows that as early as 4-6 
hours posttransfection, significant numbers of 70 kDa PEI 
grafted microparticles were in the cytoplasm while high num 
ber of the unmodified particles (red) appears to be associated 
with or surrounded by the LAMP-1 molecules (green), indi 
cating phagolysosomal presence. This Supports the hypoth 
esis that PEI conjugation on the surface of PLGA micropar 
ticles could lead to their preferential escape from the 
endolysosomal compartments. We did not see a significant 
portion of the PEI 25 kDa conjugated PLGA microparticles 
free from localization with phagosomes. This data Supports 
the buffering experiment conducted which clearly indicated 
that the PEI 70 kDa imparts significantly higher buffering 
when compared to the PEI 25 kDa branched PEI. Taken 
together, the results from FIG. 11 and FIG. 12 indicate that 
PEI conjugation likely enhances plNA delivery into the 
cytosol and should lead to more efficient transfection of den 
dritic cells. 
Covalent conjugation of PEI to PLGA particles produces 
non-cytotoxic delivery vehicles: In vitro cytotoxicity was 
evaluated using RAW macrophage cells with increasing 
doses of PEI-micro-particle concentrations (0.25, 0.5 and 1 
mg/mL) as well as with free PEI in doses equivalent for 
delivery of same amounts of pDNA to cells. These concen 
trations of polymeric particles were chosen from an estimated 
pDNA loading of 10 ug/mg and an equivalent pIDNA dose of 
500, 1000 and 2000 ng/well. The PEI amounts were for 
equivalent amount of pDNA dose using a 9:1 N.P ratio. As 
shown in FIG. 13, PEI-conjugated PLGA microparticles 
were nontoxic in comparison with free PEI. This demon 
strates that covalent immobilization on a solid Surface could 
effectively minimize the toxicity of PEI molecules. 
pDNA can be efficiently loaded on surface-modified 
PLGA microspheres: As shown in FIG. 14(A), efficient sur 
face loading of pDNA was achieved in PEI-conjugated PLGA 
particles. PEI 70 k-conjugated particles showed an average 
loading of 8 ugp)NA/mg of formulation while PEI 25k-con 
jugated particles had an average loading of 6 ug/mg. The 
target loading being 1% w/w, the loading efficiency was 
70-90% for PEI 70 k and 50-80% for PEI 25 k. The loading 
was confirmed by both direct and indirect assays as described 
above. 
pDNA and model proteins can be simultaneously delivered 
using PEI-conjugated particles: FIG.14(B) demonstrates that 
multiple biomolecules can be delivered simultaneously to the 
same cell using the proposed formulation. FITC-labeled BSA 
was encapsulated within PLGA microparticles during the 
double emulsion process followed by Surface conjugation of 
PEI. Following p)NA loading, the microparticles were 
stained with DAPI and visualized under confocal micro 
scope. As shown, coloading of both plNA (left and right 
image, blue staining) and FITC-BSA (right image, green 
staining) was successfully achieved using the Surface func 
tionalized particles. 
PEI-grafted PLGA microparticles efficiently transfect 
phagocytic cells: Total RNA from pgWiz, B-galactosidase 
DNA treated murine cells were isolated 24 hours posttrans 
fection. Transfection was conducted in full (serum contain 
ing) culture medium. As illustrated in FIG. 15(A), beta gal 
amplicon was detected only for the RNA extracts from cells 
treated with the PEI-conjugated PLGA microparticles carry 
ing the plNA. Negative controls with no RT enzyme showed 
no plNA contamination. Beta Actin expression (housekeep 
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ing gene) was used as a positive control. It is evident from the 
result that efficient transfection of phagocytic cells can be 
achieved within 24 hours of incubation using cationic micro 
particles. 
Quantification of luciferase protein expression in phago 
cytic cells with 300 and 900 ng?well dose of pDNA adsorbed 
on PEI-conjugated PLGA microparticles were determined. 
RAW macrophage cells were successfully transfected as 
detected by luminescence activity in picograms/milligram of 
total protein content (FIG. 15(B)). However, using plNA 
encapsulated PLGA particle treated cells for comparison, we 
failed to detect any luciferase activity in the 300 ng dose level. 
Although the encapsulated-p NA formulations generate sig 
nificant immune response in vivo and in clinical trials, mini 
mal or no transgene expression is detected in vitro at low 
DNA doses. This could possibly be attributed to the delayed 
release kinetics and low bioavailability of the plNA from 
encapsulated formulations. 
Example 4 
An example of a combinatorial delivery polymer, accord 
ing to one embodiment of the present disclosure, may be 
formed and studied as follows. 
Preparation of Surface-Modified Biodegradable Particles 
on which plNA and CpG oligonucleotides can be loaded and 
evaluate their ability to enhance dendritic cell transformation. 
Synthesis of PLGA microparticles: PLGA microparticles 
will be prepared as described above. 
PEI conjugation: As described above, an optimized carbo 
diimide chemistry will be used to conjugate either branched 
or linear PEI to the surface COOH groups of acid-capped 
PLGA microparticles. Briefly, 20 mg of PLGA micropar 
ticles will be suspended in 800 ul of 0.1 M MES (2-(N- 
morpholino)ethane sulfonic acid) buffer (pH 5). EDC and 
water soluble sulfo-NHS ester (>25 molar excess of the 
weight of PLGA) will be added to the PLGA particle suspen 
sion for 2 hours at room temperature. 5 molar excess of bPEI 
(70 kDa, PA, 25 kDa, Aldrich, Milwaukee, Wis.) or 3 molar 
excess of linear PEI would be diluted in 14 mL of 0.1MMES 
buffer pH 6.5 and reacted with the activated PLGA micropar 
ticles for 3 hours at room temperature. The PEI conjugated 
microparticles will be washed 4x in 1M NaCl to remove 
physically adsorbed PEI. The resulting microparticles will be 
lyophilized and stored at -20°C. until further use. 
Particle characterization: Surface functionalization with 
PEI will be verified using a variety of analytical techniques, as 
described above. 
Zeta potential: Zeta potential is an indirect estimation of 
the Surface charge by estimating the shear or Stern layer 
potential of the electrokinetic unit formed when micropar 
ticles are Suspended in a salt solution. Zeta potential analysis 
would be done as describe above. Briefly, 100 ul of a 1 lug/mL 
suspension of PLGA microparticles, with and without PEI 
conjugated to the surface, would be diluted in 1 mM KCL. 
Readings will be taken in duplicate runs (5 each time) for the 
same sample and averaged. 
Sizing Using Dynamic Laser Light Scattering (DLLS): 
The microparticles synthesized would be sized using DLLS 
(BrookHaven Instruments, Holtsville, N.Y.). Briefly, 1 g/mL 
suspension of PLGA microparticles would be diluted 1:3 and 
readings would be taken at a temperature of 25°C. with a 
scattering angle of 90° C. for 120 seconds. The number aver 
age distributions of sizes would be obtained using the NNLS 
algorithm incorporated in the ZetaPlus software. 
SEM and TEM. Scanning and transmission electron 













Briefly, for TEM, a dilute suspension of PLGA microparticles 
would be air dried on 200 mesh carbon coated copper grids. 
1% uranyl acetate would be used for negative staining of 
particles. For SEM, particles will be deposited on double 
sided carbon tapes and sputter coated with 60/40, gold/palla 
dium before imaging. 
Fourier Transform Infrared Spectroscopy (FT-IR): In order 
to confirm the presence of branched PEI and linear PEI on the 
surface of the microspheres, FT-IR would be used to investi 
gate the presence of Surface amine groups. Briefly, freeze 
dried surface modified PLGA microparticles would be mixed 
with FT-IR grade Potassium Bromide (Sigma Aldrich) with a 
ratio of 1:150 mg. KBr Pellets would be read immediately 
using a Nicolet Magna IR-560 FT-IR spectrophotometer. The 
readings would be taken at 4 cm resolution with 100 scans 
per sample. The FT-IR spectra would be analyzed for stretch 
ing and bending peaks of the primary and secondary amines 
in the backbone of the conjugated PEI. 
Fluorescamine Assay for Quantification of PEI: Fluores 
camine is a well established reagent that has been used for 
calorimetric quantification of primary amines and has been 
used to quantify PEI associated with microparticles. 
Branched PEI conjugated microparticles would be dissolved 
in 0.1N NaOH and used for measuring the PEI content by 
spectrofluorometric analysis. Fluorescamine reacts with pri 
mary amines in PEI to form a colored product which is 
excited at 390 nm and has an emission peak at 475-490 nm. 
PEI amounts wit/wt of PLGA microparticles would be esti 
mated using standard curves of stock branched PEI. 
Nucleic acid loading on cationic microparticles: pdNA or 
CpG oligonucleotide adsorption would be conducted using 
an overcompensation loading technique. Briefly, 2.5 mg of 
Surface-functionalized microparticles would be suspended in 
0.5 mL of PBS (pH adjusted to 6.0 to ensure protonation of 
the surface amine groups). 37.5ug of pDNA (pgWiz-HBs.Ag, 
Aldevron LLC, ND) alone or 19 ug of pDNA and 19 Jug CpG 
ODN (5'TCCATGACGTTCCTGACGTT-3', Oligos Etc. 
OR) (SEQID NO:1), would be suspended together in 0.5 mL 
of PBS pH 6.0. The microparticle suspension would then be 
added drop wise using a 27 1/2G insulin Syringe (Beckton and 
Dickinson, USA) to the pDNA solution under mild vortexing. 
The nucleic acid loading would be continued on an end to end 
shaker for 12 hours at 4°C. The loaded microparticles would 
be separated by centrifugation and used for further analysis 
and use. 
Analysis of nucleic acid loading: Microparticles loaded 
with only plNA would be analyzed using both direct and 
indirect spectrophotometric approaches. In the indirect 
method, Supernatants after each wash during plNA loading 
would be collected and analyzed for DNA content by absor 
bance readings at 260 nm on a UV-VIS spectrophotometer 
(Beckmann DU-530 Life Science, Single Cell Module). 
pDNA loading on the microparticles are calculated by sub 
tracting the plNA content in the Supernatant from the amount 
added initially. For direct estimation of plNA loading on the 
microparticles, the DNA-loaded microparticles would be dis 
solved in 0.1N NaOH. The resulting solution would be ana 
lyzed for plNA content using absorbance readings at 260 nm 
and using PicoGreen fluorometric estimation (Molecular 
Probes, OR) 
Simultaneous-loading of pDNA and CpG oligo on same 
microparticle surface will be analyzed by HPLC using meth 
ods previously developed as described in Roy, et al., MolTher 
7:401-8 (2003). Briefly, nucleic acid loaded particles will be 
dissolved in 1N NaOH. The resulting sample will be sub 
jected to HPLC separation using a DNA-NPR (Tosoh-Biosep 
Inc.) anion exchange column with a gradient elution (Buffer 
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A: 0.56M sodium chloride in 50 mM Tris, pH 9.0: Buffer B: 
1.2 M sodium chloride in 50 mM Tris, pH 9.0: 0-30% Buffer 
B in 15 minutes). A standard curve will constructed with the 
input plNA and CpG oligonucleotide diluted in PBS at vari 
ous concentrations. 
Does PEI-PLGA particles enhance dendritic cell transfec 
tion?: As shown above in Example 3, we have demonstrated 
that PLGA-PEI microparticles can efficiently transfect 
phagocytic cells using both mRNA and protein expression 
assays. The transfection efficacy of these particles further 
may be evaluated using bone marrow derived dendritic cells 
(BMDCs) and the therapeutic hepatitis B surface antigen 
(HBSAg) plasmid (pgWiz-HBs.Ag, Aldevron LLC, ND). 
Formulate nucleic acid-loaded particles along with the 
dendritic cell chemo-attractant MIP-3C. in an injectable, bio 
degradable polymer network and evaluate dendritic cell 
chemo-attraction, migration, and activation using in vitro and 
in vivo models. 
MIP-3C. is a well characterized chemokine for cutaneous 
and mucosal Langerhans cells as well as CD34 HPC 
derived APCs. It is a ligand for CCR6, a cell surface receptor 
primarily expressed in immature Langerhans cells. It is 
upregulated in inflamed or damaged epithelium, leading to 
migration of immature and precursor Langerhans cells at the 
site leading to antigen loading. MIP-3C. is a direct mediator of 
Langerhans cells chemotaxis and hence is a rational choice 
for this cutaneous formulation. 
BMDCs will be generated from bone marrow cells of 4-8 
weeks old BALB/c mice as previously described in Lutz, et al. 
J Immunol Methods 223:77-92 (1999). Briefly, marrow will 
be isolated using sterile techniques from the tibia and femur 
of euthanized mice. Bone marrow cells will be cultured at 
2x105 cells/mL with 10 mL in a 100 mm bacterial petri dish. 
Granulocyte monocyte colony stimulating factor (GM-CSF) 
would be added at 20 ng/mL on day 0, 3 and day 6. On day 7 
immature dendritic cell would be isolated using magnetic 
separation (DynabeadsTM (Dynal Biotech) labeled with 
CD11c antibody (Ebiosciences, CA)), and used in subsequent 
assays. PLGA-PEI particles will be directly compared for 
gene delivery and protein expression efficacy with PLGA and 
pDNA encapsulated PLGA microparticles, two existing par 
ticle-based formulations for delivery of DNA vaccines. These 
particles will be synthesized according to published proto 
cols. ppgWiz-HBSAg (Aldevron Inc.) will be adsorbed on 
PLGA-PEI and PLGA-CTAB particles or encapsulated in 
unmodified PLGA microparticles as described before. Equal 
pDNA doses will be added to each well of BMDC cells. Cells 
will be analyzed for mRNA levels of HBSAg using quantita 
tive RT-PCR (Invitrogen) at various intervals (1, 2, and 3 
days) after transfection according to manufacturer's protocol. 
Can PEI-functionalized PLGA particles, carrying surface 
pDNA/CpG activate immature dendritic cell?: Activation of 
immature dendritic cell with various microparticle-based for 
mulations will be evaluated using a method described in 
Little, et al. Proc Natl Acad Sci USA 101:9534-9 (2004). 
Primary BMDCs (isolated as described before) will be cul 
tured at 1x10° cells/well in six-well plates. A suspension of 
different microparticle formulations (50 ug?well) will be 
added to the culture medium and incubated for 24 hours. 
PLGA-PEI (branched) with or without surface-loaded 
pDNA, PLGA-PEI (linear) with or without surface-loaded 
pDNA, PLGA-PEI surface loaded with both pPNA and CpG 
oligonucleotides, pIDNA encapsulated PLGA microparticles 
and PLGA-CTAB microparticles with surface loaded plNA 
will be used. Untreated cells will be used as negative controls 
while LPS (100 ng/mL, Sigma) will be used as positive con 













stained with antibodies against F4/80, mCD40, mCD86, 
mCD80, and m41BBL (e-Bioscience, CA) at 4° C. for 30 
minutes and analyzed with a FACScan flow cytometer (Bec 
ton Dickinson). Increase in expression of various Surface 
markers (and decrease in F4/80) will be used as evidence for 
dendritic cell activation. 
In-situ crosslinking polymer networks and in vitro release 
studies: We propose a degradable depot system that is easy to 
fabricate, cost effective and could be highly efficacious in 
Langerhans cell attraction and activation. Briefly a 3% w/v. 
solution of hydrolytically degradable tetra-functional PEG 
SH (sulfhydryl) and PEG-malaemide (custom synthesized 
from Nektar Therapeutics, AL) will be formulated in PBS. 
These polymers are chosen to avoid cross-reactivity with the 
MIP-3C. itself during hydrogel formation since all members 
of the known chemokines have cysteine's in the disulphide 
forms without any free reduced SH. pl.)NA loaded micropar 
ticles along with soluble MIP-3C. will be suspended in the 
PEG-SH phase. The amount of MIP-3C. in the hydrogel 
would be optimized based on subsequent in vitro and in vivo 
assays. Immediately prior to administration, the PEG-SH/ 
microparticle/MIP-3C. formulation will be mixed with the 
PEG-malemide solution to ensure PEG crosslinking and 
hydrogel formation. Detailed physico-chemical studies on 
similar systems described in Roy, et al. Mol Ther 7:401-8 
(2003), have shown the kinetics of gelation and have demon 
strated that such a formulation is injectable and act as a slow 
release depot system with tunable release kinetics. This 
crosslinking formulation will be used for in vitro and in vivo 
studies of Langerhans cell activation and antigen presenta 
tion as well as for parallel studies on immune response. 
The release kinetics of MIP-3C. from the polymer network 
and the degradation behavior of the hydrogel should be char 
acterized in order to understand the process of chemo-attrac 
tion and particle uptake. In order to evaluate MIP-3C. release 
from the crosslinked 3% network, hydrogels with soluble 
MIP-3C. will be pre-formed at 37°C. in microfuge tubes (in 
triplicates) with various initial amounts of the chemokine (10. 
20, 50, 100 and 500 ng). 1 mL of PBS will be added to the 
tubes, followed by incubation at 37°C. At various time points 
(1 hr 1 d, 3d, 5 d, 7 d. 10d., 14 d. 21 d) 200 uL of the buffer 
solution will be retrieved and replaced with fresh buffer. 
Amount of MIP-3C. released would be analyzed using the 
murine CCL20 immunoassay kit (R&D Systems, MN., Cata 
log Number MCC200) according to the manufacturer's pro 
tocol. Briefly, 50 ul of sample would be added to the ELISA 
plates (pre coated with capture antibody towards MIP-3C) 
containing 50 ul of the assay diluent and incubated for 2 
hours. Detection would be performed using 100 ul of MIP-3C. 
detection antibody/enzyme conjugate followed by addition of 
100 ul of tetramethylbenzidine (TMB) substrate. The reac 
tion will be quenched by adding an 0.1N HCL stop solution 
and the plates would be read using a Dynatech absorbance 
plate reader at 450 nm using 570 nm as the reference filter. 
Evaluating dendritic cell migration-Transwell chamber 
model: Since our target cell population in vivo are immature 
epidermal Langerhans cells, we propose to use Langerhans 
cells directly isolated from mouse skin to quantitatively 
evaluate cell migration in response to Sustained release of 
MIP-3C. from the cross linked polymer networks. Immature 
Langerhans cells will be isolated obtained from mouse ears 
by a method similar to that described in, Peiser, et al., J 
Immunol Methods 279:41-53 (2003) and Saeki, et al. Eur J 
Immunol 30:2808-14 (2000), using magnetic separation. 
Briefly, skin from BALB/c (4-8 weeks old) mice will be 
Surgically removed, incubated in dispase I (Roche, 18 hour, 
4°C.) to remove the dermal layer followed by preparation of 
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cell suspension in 0.25% trypsin (37°C., 15 minutes) along 
with vigorous pipetting and passage through a 40 um cell 
strainer. Langerhans cells will be isolated using a rat anti 
mouse Cala antibody (Pharmingen) conjugated to magnetic 
microbeads (Dynabeads, Dynal Biotech)). 
Chemotaxis assays will be performed as detailed in Kuma 
moto, et al. Nat Biotechnol 20:64-9 (2002). Transwell cham 
bers (6.5 mm, Costar, Cambridge, Mass.) with a pore size of 
5 um will be used to study migration of Langerhans cells. 
Crosslinked hydrogels, as described in the previous section, 
will be loaded with various amounts of MIP-3C (0, 3, 10, 30, 
60, 100 and 300 ng). The hydrogels will be placed at the 
bottom of the Transwell chamber and dendritic cell will be 
added to the filter unit. At various time points after incubation 
(2h, 6 h, 12 h, 1 d, 3d, 5 d) migratory cells will be harvested 
from the lower chambers and counted using flow cytometry 
for CD11c-- cells. The percentage of dendritic cell migrated 
will be calculated by dividing the number of CD 11c-- cells 
collected from the bottom chamber by the total CD11c-- cells 
initially added to the upper chamber. A migration kinetics 
curve plotting cumulative number of migrated dendritic cell 
versus time will be used to evaluate optimal MIP-3C. dose. 
The dose at which the largest number of Langerhans cells 
migrate into the bottom well will be used for further in vivo 
studies. 
Evaluating Langerhans cell attraction and activation: Skin 
model: In order to test our hypothesis that sustained release of 
MIP-3C can attract epidermal Langerhans cells and increase 
microparticle delivery to Langerhans cells, we propose to 
use an in Vivo Langerhans cell activation assay using murine 
ear skinas a model system and evaluate whether the polymer 
formulations containing MIP-3C. induces efficient Langer 
hans cell migration to the plNA carrying microparticles and 
increases particle uptake. Formulations (microparticle/MIP 
3.C. or polymer networks carrying particle and soluble MIP 
3.C. will be injected into the ear of BALB/c mice (4-8 weeks 
old). All microparticles will be loaded with plNA and stained 
as detailed in the previous section. The ear tissue will be 
excised at various time points (10 min, 30 min, 1 hr., 3 hrs, 6 
hrs, 12 hrs and 24 hrs) followed by epidermal sheet prepara 
tion an dendritic cell staining with the I-A antibody, as 
described in Gu, et al., J. Drug Del. Sci. Tech 14:265-273 
(2004). Particle-Langerhans cell localization and particle 
uptake by Langerhans cells will be evaluated using confocal 
microscopy (Leica) of epidermal sheets. We plan to use con 
centrations of MIP-3C. optimized through the in vitro experi 
ments described in the previous section. However, we would 
also vary the MIP-3C concentration around this optimized 
amount in order to reconfirm that we have arrived at an 
optimal formulation that can be used for immunization stud 
1CS 
For quantitative comparison, each confocal Z-series sec 
tions with fluorescently immunostained dendritic cells and 
fluorescently labeled poNA carrying particles will be ana 
lyzed. Dendritic cell migration (and chemo-attraction) will be 
evaluated by manually counting the number of cells present in 
a given field of view using a 10x objective. The data will be 
summed over all Z-section for a specific field of view and 
expressed as total number of cells per field. This will be 
repeated over 10 random fields of view around the site of 
injection and the average number of particles perfield will be 
used as a quantitative measure of dendritic cell migration. 
Graphs indicating number of cells/field plotted against time 
(minutes after formulation administration), as shown in the 
preliminary data section, will be used to evaluate the kinetics 
and magnitude of dendritic cell migration. Since we also 
expect that epidermal Langerhans cells will phagocytose the 
particles, get activated and emigrate from the tissue to the 













and evaluate both Langerhans cell attraction and activation 
(i.e. migration away from the site following particle inges 
tion). 
We expect that compared to particle formulations carrying 
no MIP-3C., MIP-3C. coencapsulated with particles in the 
network formulation will have enhanced Langerhans cell 
migration leading to increased particle delivery to Langer 
hans cells. Both the in vitro transwell model and the in vivo 
skin-based experiments would allow us to optimize the 
amount of MIP-3C. necessary for in vivo immunization stud 
1CS 
If Langerhans cell isolation poses a significant challenge, 
we will use splenic dendritic cells, freshly isolated from 
spleens of BALB/C mice. plenic dendritic cells will be iso 
lated from freshly harvested spleens of BALB/C mice (6-9 
weeks old, female, Jackson Labs, ME). Briefly, cell suspen 
sions will be prepared by mechanically dissociating the 
spleen (in 1% FBS/HBSS) using forceps, followed by colla 
genase treatment (1% collagenase, NJ for 1 hour 37°C.) and 
erythrocyte lysis (3 minutes in 3 mL of ACK lysis buffer, 
BioWhittaker, MD). A DynabeadTM (Dynal Biotech) mag 
netic separation process using a monocolonal antibody 
against CD11c (Ebiosciences Inc, CA) will be used to posi 
tively select dendritic cells according to standard protocols 
(Dynal Biotech). 
In vivo immunization using Surface-modified polymer par 
ticles with or without sustained release of MIP-3C. and evalu 
ate adjuvant effects of the polymer formulations. 
Preliminary studies on in vivo immunization with formu 
lations developed as described above will be carried out in 
order to evaluate the adjuvant effects of the proposed poly 
meric delivery systems and to correlate immune response 
with the dendritic cell activation and Langerhans cell migra 
tion data. We will use a plasmid encoding for the hepatitis B 
surface antigen (pgWiz-HBSAg, Aldevron LLC, ND) as 
model DNA vaccine. The following variables are proposed in 
the formulation design and needs to be evaluated along with 
appropriate controls: (a) branched versus linear PEI, (b) 
molecular weights of branched PEI, (c) plNA dose, (d) co 
delivery of CpG oligonucleotides with plNA in the same 
particles, (e) co-delivery of MIP-3C. in degradable networks, 
and (e) MIP-3C. dose. The following criteria will be used to 
determine which formulations will be tested for animal stud 
ies: (i) In-vitro transfection of RAW cells and BMDC's will 
be used to select for the optimal molecular weight of branched 
PEI, (ii) The Transwell and quantitative microscopy assays 
described above will be used to identify optimal dose of 
MIP-3C. The top two doses of MIP-3C. producing most potent 
dendritic cell attraction will be used for further in vivo analy 
S1S. 
We propose to use three sets of preliminary experiments to 
identify effective formulations. The following tables summa 
rize the experimental design for these studies. All groups will 
be given one booster application at 3 weeks after the first 
immunization using the same dose of pDNA. Each set of 
experiments will be repeated twice to ensure reproducibility. 
Study 1, Comparison between branched and linear PEI and 
optimization of pDNA dose is shown in Table 3. 
TABLE 3 
Number 
Description pDNA dose? mouse of mice 
Group 1 Saline Control O 5 
Group 2 Recombinant HBSAg 0 (0.8 ug?mice protein 5 
with Alum dose, Subcutaneous) 
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TABLE 3-continued 
Number 
Description pDNA dose? mouse of mice 
Group 3 Naked poNA 1, 10 or 50 ug 5 per dose 
Group 4 PLGA-bPEI-pHBSAg 1, 10 or 50 ug 5 per dose 
Group 5 PLGA-IPEI-pHBSAg 1, 10 or 50 ug 5 per dose 
At the completion of Study 1 (with two repeats) we would 
choose the PEI formulation and plNA dose generating the 
highest immune response. This formulation will be used for 




Description pDNA dose? mouse of mice 
Group 1 Saline Control O 5 
Group 2 Recombinant HBSAg 0 (0.8 ug?mice protein 5 
with Alum dose, Subcutaneous) 
Group 3 Naked poNA Optimized dose from Exp1 5 
Group 4 PLGA-optimized PEI- Optimized dose from Exp1 5 
pHBSAg 
Group 5 PLGA-optimized PEI- Optimized dose from Exp1 5 
pHBSAg+ co-loaded 
CpG 
At the conclusion of Study 2, we would decide if CpG 
oligonucleotides, co-loaded on the same polymer particles 
provides any additional immunological benefit. If no signifi 
cant difference is observed, subsequent studies will use 
pDNA alone. Study 3, shown in Table 5 will ask: Can sus 
tained release of delivery of MIP-3C. enhance immune 
response? 
TABLE 5 
Description pDNA dose? mouse 
Group 1 Saline Control O 
Group 2 Recombinant HBSAg with 0 (0.8 ug mice protein dose, 
Alum Subcutaneous) 
Group 3 Naked pCNA Optimized dose from Exp1 
Group 4 PLGA-optimized PEI-pHBSAg- Optimized dose from Exp1 
optimized CpG (from Exp 2) 
Group 5 PLGA-optimized PEI-pHBSAg- Group 5 
optimized CpG (from Exp 2) + MIP 
3 in hydrogel dose 1 
Group 6 PLGA-optimized PEI-pHBSAg- Optimized dose from Exp1 
optimized CpG (from Exp 2) + MIP 
3 in hydrogel dose 2 
Group 7 PLGA-optimized PEI-pHBSAg- Optimized dose from Exp1 
optimized CpG (from Exp 2) + bolus 
MIP-3 dose 1 
Group 8 PLGA-optimized PEI-pHBSAg- Optimized dose from Exp1 
optimized CpG (from Exp 2) + bolus 
MIP-3 dose 2 
At the end of these experiments the top two formulations 
showing the highest immunological response will be further 
evaluated using 15 mice per group to establish reproducibility 
and variability. 
Immunological assays performed for each immunization 
experiment: At 3, 6, and 9 weeks after initial immunization, 
blood (-60 ul/mouse) will be collected via retro-orbital 
bleeding. Serum levels of anti-HBs.Ag antibodies (total IgG, 
IgG2a, IgG1 and IgG3) will be measured by ELISA using 
anti-mouse secondary antibodies (Southern Biotech Inc.) 
Briefly, 50 ul of a 2 ug/mL solution of recombinant HBSAg 









high binding ELISA plates. (Costar, Fisher Scientific). Plates 
would be washed 2x with PBST (containing 0.05% Tween 
20) and blocked subsequently with PBS containing 1% BSA 
for 2 hours at room temperature and washed. Control mouse 
serum, serial dilutions of recombinant HBSAg specific 
monoclonal antibody (Clone NF5 (Aldevron, N. Dak.) for 
standard curve) and serial dilutions of serum samples from 
immunized mice would be incubated for 1.5 hour at room 
temperature. HRP conjugated rabbitantimouse IgG would be 
used as the secondary antibody and developed using TMB. 
Following the 9-week bleeding, mice will be euthanized 
and the spleen and lymph will be collected and assayed for 
antigen specific responses. This will include MHC Class II 
restricted T cell proliferation response and MHC Class I 
restricted ELISPOT assays for cytokine release assays 
(mouse IFN-gamma ELISPOT, BD Biosciences, Cat 
#55 1083). Spleen and lymph nodes from each group would 
be pooled together, crushed with the rear end of a 5 cc syringe 
plunger and passed through a 70 um cell strainer (BD Bio 
sciences, Cat #352350) to obtain single cell suspensions. 
Spleen Suspensions would be seeded at varying cell numbers 
and pulsed with recombinant HBSAg protein (Clone NF5 
(Aldevron, LLC, ND), with ovalbumin as negative control 
and Concanavalin Aas positive control (Sigma Aldrich, MO), 
incubated for 20 hours with H thymidine and would be 
counted with a beta plate reader following cell harvesting. For 
MHC class I restricted CD8" T cell response spleen suspen 
sions prepared as before would be pulsed with MHC class I 
restricted peptides and control peptides for HBS Ag, IPOSLD 
SWWTSL, the H-2L" epitope corresponding to residues 
28-39 of HBSAg (Multiple Peptide Systems, CA), a 9mer 
H-2L'restricted epitope encoding for the 876-884 amino acid 
residues from the B-galactosidase protein would be used as 
Number of mice 
the negative control and Concanavalin A would be used as the 
positive control. Following 24 hours of incubation, gamma 
interferon ELISPOT assay will be performed according to 
manufacturer's protocol (BDBiosciences, CA). All formula 
tions will be evaluated for strength, duration, and nature of 
immune response. 
While embodiments of this disclosure have been depicted, 
described, and are defined by reference to example embodi 
ments of the disclosure, Such references do not imply a limi 
tation on the disclosure, and no such limitation is to be 
inferred. The subject matter disclosed is capable of consider 
able modification, alteration, and equivalents inform and 
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function, as will occur to those ordinarily skilled in the per 
tinent art and having the benefit of this disclosure. The 
depicted and described embodiments of this disclosure are 
examples only, and are not exhaustive of the scope of the 
disclosure. 
SEQUENCE LISTING 












OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 1 
tccatgacgt toctdacgtt 
What is claimed is: 
1. A particle composition comprising: 
a poly(lactide-coglycolide) (PLGA) microparticle or 
nanoparticle comprising: 
a plurality of PLGA polymers covalently surface function 
alized by a plurality of polyethyleneimine (PEI) moi 
eties in a graft copolymer. 
2. The particle composition of claim 1, further comprising 
at least one agent chosen from a therapeutic agent, a diagnos 
tic agent, an imaging agent, a nucleic acid, a plNA, an 
immunomodulatory agent, a cytokine, a chemokine, a 
chemo-attractant, an siRNA, a CpG oligonucleotide, a pro 
tein, and a peptide. 
3. The particle composition of claim 1, further comprising 
a biodegradable polymer network, in which the microparticle 
or nanoparticle may be entrapped. 
4. The particle composition of claim 1, wherein the plural 
ity of PEI moieties is capable of enhancing the transfection of 
the particle composition. 
5. The particle composition of claim 1, further comprising 
at least one targeting ligand. 
6. The particle composition of claim 1, further comprising 
at least one targeting ligand chosen from a Sugar, a mannose, 
a fructose, a galactose, a protein, a monoclonal antibody, and 
a fragment thereof. 
7. A combinatorial delivery polymer comprising: 
a poly(lactide-coglycolide) (PLGA) microparticle or 
nanoparticle comprising a plurality of PLGA polymers 
covalently surface functionalized by a plurality of poly 
ethyleneimine (PEI) moieties in a graft copolymer; and 
a plurality of nucleic acids electrostatically bonded to the 
PEI moieties in the particles. 
8. The combinatorial delivery polymer of claim 7, wherein 
the nucleic acids comprise at least one molecule chosen from 
an siRNA, a plNA and a CpG oligonucleotide. 
9. The combinatorial delivery polymer of claim 7, wherein 
the microparticle or nanoparticle further comprises at least 
one agent chosen from a therapeutic agent, a diagnostic agent, 
an imaging agent, an immunomodulatory agent, a cytokine, a 
chemo-attractant, a protein, and a peptide. 
10. The combinatorial delivery polymer of claim 7. 
wherein the microparticle or nanoparticle further comprises 
at least one targeting ligand. 
11. The combinatorial delivery polymer of claim 7. 











at least one targeting ligand chosen from a Sugar, a mannose, 
a fructose, a galactose, a protein, a monoclonal antibody, and 
a fragment thereof. 
12. The combinatorial delivery polymer of claim 7, further 
comprising a plurality of chemokine molecules. 
13. The combinatorial delivery polymer of claim 7, further 
comprising a biodegradable polymer network, in which the 
microparticle or nanoparticle and a plurality of chemokine 
molecules may be entrapped. 
14. The combinatorial delivery polymer of claim 12, 
wherein the plurality of chemokine molecules comprises at 
least one molecule chosen from MIP-3?, MIP-3C, a mono 
cyte chemotactic protein, MCP-1, and MCP-3. 
15. The combinatorial delivery polymer of claim 13, 
wherein the biodegradable polymer network is an in situ 
crosslinking, biodegradable, hydrogel network. 
16. The particle composition of claim 1, wherein the micro 
particle or nanoparticle has a Zeta potential of at least 1 mV at 
pH 7.4 in 1 mM HEPES buffer. 
17. The combinatorial delivery polymer of claim 7. 
wherein the microparticle or nanoparticle has a Zeta potential 
of at least 1 mV at pH 7.4 in 1 mM HEPES buffer. 
18. A particle composition comprising: 
a poly(lactide-coglycolide) (PLGA) microparticle or 
nanoparticle comprising: 
a plurality of PLGA polymers covalently bonded to the 
PEI moieties in a graft copolymer 
wherein the microparticle or nanoparticle is operable to 
electrostatically bind a nucleic acid via the PEI moieties. 
19. The particle composition of claim 18, further compris 
ing at least one agent chosen from a therapeutic agent, a 
diagnostic agent, an imaging agent, a nucleic acid, a plNA, 
an immunomodulatory agent, a cytokine, a chemokine, a 
chemo-attractant, an siRNA, a CpG oligonucleotide, a pro 
tein, and a peptide. 
20. The particle composition of claim 18, further compris 
ing a polymer network. 
21. The particle composition of claim 18, wherein the 
plurality of PEI moieties is capable of enhancing the trans 
fection of the particle composition. 
22. The particle composition of claim 18, further compris 
ing at least one targeting ligand. 
23. The particle composition of claim 18, further compris 
ing at least one targeting ligand chosen from a Sugar, a man 
nose, a fructose, a galactose, a protein, a monoclonal anti 
body, and a fragment thereof. 
24. The particle composition of claim 18, further compris 
ing a particulate carrier system or a drug particle. 
25. The particle composition of claim 18, wherein the 
microparticle or nanoparticle has a Zeta potential of at least 1 
mV at pH 7.4 in 1 mM HEPES buffer. 
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26. The particle composition of claim 1, wherein the PEI is 28. The particle composition of claim 18, wherein the PEI 
attached to the PLGA via carbodiimide chemistry. is attached to the PLGA via carbodiimide chemistry. 
27. The combinatorial delivery polymer of claim 7. 
wherein the PEI is attached to the PLGA via carbodiimide 
chemistry. k . . . . 
